Drugs / Human fibrinogen concentrate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01283321 | Jan 2011 → May 2013 | coronary artery disorder, heart valve disorder | Emory University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02094430 | Jan 2014 → Dec 2015 | congenital afibrinogenemia | LFB | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01487837 | Jan 2012 → Oct 2014 | blood coagulation disease, hemorrhagic disease | University Children's Hospital, Zurich | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT04602689 | Oct 2020 → Jul 2022 | gastric adenoma, gastric carcinoma | Seoul National University Hospital | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human fibrinogen concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602689 ↗ |
| Known as | FGTW | “Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency” NCT02094430 ↗ |
| Modality | Protein / enzyme biologic | “purified lyophilized human fibrinogen concentrate versus conventional transfusion.” PMID 23718572 ↗ May 2013 |
| Route | Intravenous | “4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding” NCT01283321 ↗ |